Antileukocyte antibodies detected in plasma from TRALI and control donors
| . | No. of cases . | Test results for total n . | No. of cases with positive results . |
|---|---|---|---|
| Antigranulocyte antibodies | |||
| TRALI donors (n = 104) | 28 | 16 weakly positive3-150 | 4 |
| Control donors (n = 24) | 5 (no reaction) | 3 weakly positive | 2 |
| Anti–HLA class I antibodies | |||
| TRALI donors (n = 104) | 28 | 1 moderately positive3-151 | 1 |
| Control donors (n = 24) | 5 (no reaction) | 0 positive | 2 |
| Anti–HLA class II antibodies (n = 75 TRALI donors) | 20 | 5 moderately positive3-152 | 5 |
| . | No. of cases . | Test results for total n . | No. of cases with positive results . |
|---|---|---|---|
| Antigranulocyte antibodies | |||
| TRALI donors (n = 104) | 28 | 16 weakly positive3-150 | 4 |
| Control donors (n = 24) | 5 (no reaction) | 3 weakly positive | 2 |
| Anti–HLA class I antibodies | |||
| TRALI donors (n = 104) | 28 | 1 moderately positive3-151 | 1 |
| Control donors (n = 24) | 5 (no reaction) | 0 positive | 2 |
| Anti–HLA class II antibodies (n = 75 TRALI donors) | 20 | 5 moderately positive3-152 | 5 |
Antibody testing was performed as described in “Patients, materials, and methods.”
All reactions were weak without definable specificity. Panel cells included cells positive for NA1, NA2, NB1, and NB2 antigens. Positive control antibodies included anti-NA1, anti-NA2, and anti-5b and gave strong reactions with appropriate control granulocytes.
Moderate reactions with anti-A26 specificity defined. Positive controls gave moderate to strong reactions.
Target cells included all serologically defined class II, DR types, except DR 12 and DR 14. Positive controls gave moderate to strong reactions. Of the 5 TRALI donors with positive reactions, 2 had strongly positive reactions with no definable specificity (both implicated plasmas were negative for antigranulocyte and anti-HLA class I antibodies) and 3 had weak or questionable reactions (all 3 implicated plasmas also tested nonspecifically weakly/questionably positive for antigranulocyte antibodies and were negative for anti-HLA class I antibodies).